APA (7th ed.) Citation

Al-Odat, O. S., Al-Odat, O. S., Elbezanti, W. O., Elbezanti, W. O., Gowda, K., Srivastava, S. K., . . . Pandey, M. K. (2024, October). KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis. Frontiers in Pharmacology.

Chicago Style (17th ed.) Citation

Al-Odat, Omar S., et al. "KS18, a Mcl-1 Inhibitor, Improves the Effectiveness of Bortezomib and Overcomes Resistance in Refractory Multiple Myeloma by Triggering Intrinsic Apoptosis." Frontiers in Pharmacology Oct. 2024.

MLA (9th ed.) Citation

Al-Odat, Omar S., et al. "KS18, a Mcl-1 Inhibitor, Improves the Effectiveness of Bortezomib and Overcomes Resistance in Refractory Multiple Myeloma by Triggering Intrinsic Apoptosis." Frontiers in Pharmacology, Oct. 2024.